Mechanism of Action

VRAYLAR is thought to act as a partial agonist at certain receptors

The mechanism of action of VRAYLAR is unknown. The efficacy of VRAYLAR is thought to be mediated through a combination of:

Central dopamine D2

Arrow icon.

Partial agonist

Serotonin 5-HT1A

Arrow icon.

Partial agonist

Serotonin 5-HT2A

Arrow icon.

Antagonist

The first and only dopamine and serotonin partial agonist FDA approved for the most
common forms of depression – MDD (adjunctive) and bipolar I*

*VRAYLAR is approved for adults as an ADT add-on for MDD and as a monotherapy for bipolar I depression.1


Partial Agonism

An adaptive response mechanism for modulating dopamine and serotonin receptor activity

Functional agonist activity when neurotransmitter levels are low.20

Functional antagonist activity when neurotransmitter levels are high.20

Functional agonist activity when neurotransmitter levels are low.20

Gauge showing dopamine and serotonin activity.

Functional antagonist activity when neurotransmitter levels are high.20